SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMCNet:  Harvard Apparatus Regenerative Technology Profiled by Boston's ABC-TV Affiliate on November 27

[December 02, 2013]

Harvard Apparatus Regenerative Technology Profiled by Boston's ABC-TV Affiliate on November 27

HOLLISTON, Mass. --(Business Wire)--

Harvard Apparatus Regenerative Technology, Inc. (NASDAQ: HART), a biotechnology company developing regenerative medicine therapies, initially for trachea cancer, was featured November 27 in a television segment and article reported by the ABC-TV affiliate in Boston (WCVB-TV).

The report, filmed at the Company's headquarters in Holliston, highlighted the cutting-edge science and technology involved in creating the synthetic scaffolds and bioreactors that have been used to create regenerated tracheas. The report noted that eight patients have received these tracheas since the Company's first surgery two years ago.

To watch the television segment and read the accompanying article, please visit the following link: http://www.wcvb.com/health/labgrown-human-organs-available-for-transplants/-/9848730/23191598/-/8bmp62z/-/index.html#ixzz2m3DWNuvh


About Harvard Apparatus Regenerative Technology

Harvard Apparatus Regenerative Technology is a clinical stage regenerative medicine company developing life-saving medical products. Our first product, the InBreath TM Airway Transplant System, is intended to repair a trachea that has been severely damaged by either trachea cancer or physical trauma. None of our products are yet approved by a government regulatory authority for marketing. On November 1, 2013, HART was spun-off from Harvard Bioscience. We have filed a trademark application with respect to the InBreath trademark. The trademark "Harvard Apparatus" is used under a sublicense agreement with Harvard Bioscience, who has licensed the right to use such trademark from Harvard University.

Forward-Looking Statements

Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements include statements relating to, among other things, the planned commercialization efforts and marketing approvals of HART's products as well as the success thereof and the availability of a market for the HART securities. These statements involve risks and uncertainties, including among other things, market conditions that may cause results to differ materially from the statements set forth in this press release. The forward-looking statements in this press release speak only as of the date of this press release. Harvard Apparatus Regenerative Technology expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based.


[ Back To Technology News's Homepage ]

OTHER NEWS PROVIDERS







Technology Marketing Corporation

800 Connecticut Ave, 1st Floor East, Norwalk, CT 06854 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2014 Technology Marketing Corporation. All rights reserved.